Recombinant human BCR-RET, the fusion protein [BCR (1-426)-RET (713-end)], was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag.
Catalog No. R02-19EG
| Catalog No. | Pack Size | Price (USD) | |
|---|---|---|---|
| R02-19EG-05 | 5 ug | $259 | |
| R02-19EG-10 | 10 ug | $380 | |
| R02-19EG-BULK | BULK | Contact Us |
Overview:
BCR-RET is a chimaeric fusion of BCR and RET genes generated by a balanced translocation of genes from t(10;22)(q11;q11) and this leads to aberrant activation of RET activity which can transform hematopoietic cells and skew the hematopoietic differentiation program towards the monocytic/macrophage lineage (1). The BCR-RET fusion is frequently found in chronic myelomonocytic leukemia (CMML) cases. The RET fusion genes seem to constitutively mimic the same signaling pathway as RAS mutations frequently involved in CMML.
Gene Aliases:
BCR: ALL, CML, PHL, BCR1, D22S11, D22S662, FLJ16453
RET: CDHF12, RET51, PTC, RET-ELE1; RET/PTC2
References:
1.Ballerini, P. et al: RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation. Leukemia. 2012 Nov;26(11):2384-9.
Specific Activity:
Sample Kinase Activity Plot. For specific information on a given lot, see related technical data sheet.
|
Purity:
Sample Purity Data. For specific information on a given lot, see related technical data sheet.
|
Storage, Stability and Shipping:
Store product at –70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
Molecular Weight:
140 kDa
There are no related publications available for this product.
Cancer, Receptor Tyrosine Kinases
STAY CONNECTED
Fax: 1-604-232-4601
Toll Free: 1-866-954-6273
info@signalchem.com